Physician profile
Frdaniel B Boyd
NPI 1285811687
$1,023.83
in general payments reported to CMS, 2019-2025
11 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $134 · 2021: $40.02 · 2022: $35.47 · 2023: $79.58 · 2024: $405 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $285.68 | 2020-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $175.04 | 2020-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $149.15 | 2020-2025 | Wegovy |
| Abbott Laboratories | $127.43 | 2022-2024 | Mitraclip |
| Medtronic, INC. | $89.37 | 2025 | Interstim |
| Amgen INC. | $64.96 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Baxter Healthcare | $43.87 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.02 | 2025 | |
| Exact Sciences Corporation | $23.24 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $21.55 | 2024 | |
| Genentech USA, INC. | $12.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frdaniel Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.